- $26.71bn
- $27.55bn
- $4.34bn
Illumina surges on Q3 results beat, FY profit forecast raise
Genomics company Illumina Q3 revenue beats expectations, helped by clinical market growth
Brief: Illumina Q3 Adjusted EPS USD 1.34 Vs. IBES Estimate USD 1.17
10x sues rival Illumina over gene-sequencing patents
Brief: Illumina Constellation Mapped Read Technology Uncovers Hard-To-See Genomic Insights In GeneDx Pilot
Timeline: Trump's trade war with China in 2025
Timeline: Trump's trade war with China in 2025
EU M&A rules morph from growth catalyst to weapon
Brief: Illumina Launches New Business To Accelerate Technology And Data-Driven Discovery
US. STOCKS ON THE MOVE-Vertex, IBM, Silver Miners
US. STOCKS ON THE MOVE-Vertex, IBM, silver miners
Medical device makers fall after US government probes of medical device imports
Illumina sued by rival Element over gene-sequencing technology
Timeline: Trump's trade war with China in 2025
Brief: Illumina® Protein Prep Launches To Drive Greater Proteomic Insights For Improved Drug Discovery And Development
Brief: Illumina® Protein Prep Launches To Drive Greater Proteomic Insights For Improved Drug Discovery And Development
Factbox: Healthcare firms see growing activist investor involvement in the past year
Brief: Carl Icahn Raises Shared Share Stake In Centuri Holdings, Dissolves In Dana,Illumina
Timeline: Trump's trade war with China in 2025